![](https://www.microbiometimes.com/wp-content/uploads/2019/01/shutterstock_530884738-326x245.jpg)
Vedanta Biosciences Raises $27 Million Series C Financing to Advance Clinical Pipeline of Microbiome-Derived Product Candidates
Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria, announced that it has raised $27 million in a Series C financing with […]